Prism Medico & Pharmacy Ltd

Prism Medico & Pharmacy Ltd is rated Sell by MarketsMOJO, with this rating last updated on 18 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Prism Medico & Pharmacy Ltd has experienced a notable shift in its valuation parameters, moving from a very expensive to an expensive rating, reflecting a subtle but meaningful change in price attractiveness. This reclassification comes amid mixed financial metrics and a volatile market backdrop, prompting investors to reassess the stock’s appeal relative to its peers and historical benchmarks.

Surging past its previous peaks, Prism Medico & Pharmacy Ltd touched a new 52-week high of Rs 34.49 on 29 Apr 2026, marking a remarkable 128.87% gain over the past year. This milestone comes amid a backdrop of strong technical momentum and a market environment where the Sensex trades cautiously below key moving averages.

With a remarkable 131.29% gain over the past year, Prism Medico & Pharmacy Ltd surged to a fresh 52-week high of Rs 34 on 27 Apr 2026, outpacing the Sensex which declined by 2.48% during the same period. This milestone caps a four-day winning streak that has propelled the stock up by 9.47%, underscoring a strong momentum that is supported by a confluence of technical indicators.

Surging past its previous peaks, Prism Medico & Pharmacy Ltd touched a fresh 52-week high of Rs 33.65 on 24 Apr 2026, marking a remarkable 126.56% gain over the past year. This rally stands in stark contrast to the broader market’s decline, with the Sensex down 3.48% over the same period, underscoring the stock’s strong momentum and technical resilience.

With a decisive break above its previous peak, Prism Medico & Pharmacy Ltd surged to a new 52-week high of Rs 33.58 on 21 Apr 2026, marking a remarkable 107.4% gain over the past year. This milestone comes amid a sustained rally supported by a confluence of bullish technical indicators and a broader market environment that has been steadily advancing.

Surging past its previous peak, Prism Medico & Pharmacy Ltd touched a fresh 52-week high of Rs 32.15 on 20 Apr 2026, marking a remarkable doubling in price from its low of Rs 12.49 over the past year. This milestone reflects a sustained momentum driven by a confluence of bullish technical indicators and steady market participation.

Prism Medico & Pharmacy Ltd has witnessed a marked shift in its valuation parameters, moving from an expensive to a very expensive rating, prompting a downgrade in its Mojo Grade from Hold to Sell. Despite robust price gains and outperformance against the Sensex over multiple time frames, the company’s elevated price-to-earnings and price-to-book ratios relative to peers and historical averages raise questions about its price attractiveness for investors.

Surging past its previous peaks, Prism Medico & Pharmacy Ltd touched a fresh 52-week high of Rs 31 on 13 Apr 2026, marking a remarkable 66.07% gain over the past year. This rally stands in stark contrast to the Sensex’s modest 1.17% rise, underscoring the stock’s strong momentum amid a broader market retreat.

Prism Medico & Pharmacy Ltd has reached a significant milestone by hitting a new 52-week high of Rs.30.22, marking a remarkable rally over the past year. This achievement underscores the stock’s strong momentum within the Non Banking Financial Company (NBFC) sector despite recent market fluctuations.

Prism Medico & Pharmacy Ltd has reached a significant milestone by hitting a new 52-week high of Rs.28.79, marking a continuation of its robust upward momentum in the Non Banking Financial Company (NBFC) sector. This achievement reflects a remarkable rally over the past nine trading sessions, with the stock delivering substantial returns well above sector and benchmark indices.

Prism Medico & Pharmacy Ltd has surged to a fresh 52-week high of Rs.27.42, marking a significant milestone in its stock performance. This new peak reflects sustained momentum, with the stock demonstrating robust gains over the past several sessions and outperforming its sector peers.

Prism Medico & Pharmacy Ltd, a player in the Non Banking Financial Company (NBFC) sector, reached a significant milestone today by hitting a new 52-week high of Rs.26.12. This marks a continuation of the stock’s robust momentum, reflecting a strong rally over the past week and notable outperformance relative to its sector peers.

Prism Medico & Pharmacy Ltd has surged to a fresh 52-week high of Rs.24.88, marking a significant milestone in its stock performance. This new peak reflects sustained momentum, with the stock outperforming its sector and demonstrating robust gains over recent sessions.

Prism Medico & Pharmacy Ltd, a player in the Non Banking Financial Company (NBFC) sector, has witnessed a notable shift in its valuation parameters, moving from a very attractive to a fair valuation grade. This change reflects evolving market perceptions amid mixed financial metrics and peer comparisons, prompting a reassessment of its price attractiveness for investors.

Prism Medico & Pharmacy Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 Nov 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of the company's fundamentals, returns, and technical outlook.

Prism Medico, a microcap player in the Non Banking Financial Company (NBFC) sector, has experienced a revision in its market assessment reflecting challenges in its financial health and stock performance. Recent analytical changes highlight concerns over the company’s operational results and market returns, signalling a cautious outlook for investors.